James Lee, MD

Title(s)HS Clinical Instructor, Medicine
SchoolSchool of Medicine
AddressLocation Required
Phone415-885-7276
ORCID ORCID Icon0000-0002-1762-1766 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yale University School of Medicine, New HavenM.D.-M.H.S.
    The Mount Sinai Hospital, New YorkInternal Medicine
    UCSF, San Francisco Medical Oncology
    Collapse Awards and Honors
    2006  - 2007American Medical Association Seed Grant
    2006  - 2007American Society of Hematology Trainee Award
    2007  - 2008Farr Scholar Award for Leadership and Excellence in Biomedical Research, Yale University
    2008  - 2009American Cancer Society of Connecticut Research Award
    2016  - 2017NIH Immunology T32
    2017  - 2020A.P. Giannini Fellowship Award
    2019  - 2021Parker Institute for Cancer Immunotherapy Project Award
    2021  - 2024Parker Institute for Cancer Immunotherapy Bridge Fellow Award

    Collapse Overview 
    Collapse Overview
    I have a research focus in adoptive T cell therapy using chimeric antigen receptors (CARs) and checkpoint inhibitors. My current interest is on the design of next generation of CARs and combination checkpoint immunotherapy in the setting of a tolerant/suppressive tumor microenvironment in solid malignancies.

    Translating recent advancements in cellular cancer immunotherapy to metastatic solid tumors has been especially challenging, and this is highlighted by the lack clinical response outside of the CD19 ideal antigen as target. Current forms of therapy is likely insufficient to overcome the naturally tolerogenic microenvironment evolved to protect against autoimmunity across organ sites. Using the liver as a model organ of immune tolerance, we discovered the putative mechanisms of tumor escape to checkpoint inhibitor therapy in the setting of liver metastases and are now working on developing strategies to overcome them.

    My hope is to see cancer immunotherapeutics become a mainstream form treatment that is capable of providing durable and curative responses for stage IV cancers.


    Past Professional Experience:

    Clinical Instructor, Memorial Sloan-Kettering Cancer Center, New York, NY. July 2012-July 2013

    Clinical Instructor, University of California, San Francisco, CA. July 2013-July 2014


    Education:

    Medical School: Yale School of Medicine, New Haven, CT. September 2003-May 2009

    Research Fellowship: Memorial Sloan-Kettering Cancer Center, New York, NY. 2006-2009.

    Residency: Mount Sinai Medical Center, New York, NY. July 2009-June 2012


    ABIM Board Certifications:

    Internal Medicine. 2012

    Medical Oncology. 2021

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Collaboration Interests
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. ATF7ip Targets Transposable Elements for H3K9me3 Deposition to Modify CD8+ T Cell Effector and Memory Responses. J Immunol. 2022 03 01; 208(5):1155-1169. Sin JH, Kashyap S, Acenas D, Cortez JT, Lee J, Marson A, Matloubian M, Waterfield MR. PMID: 35110421; PMCID: PMC8881383.
      View in: PubMed   Mentions:
    2. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cell Mol Immunol. 2022 01; 19(1):33-45. Huppert LA, Green MD, Kim L, Chow C, Leyfman Y, Daud AI, Lee JC. PMID: 34417572; PMCID: PMC8752797.
      View in: PubMed   Mentions:    Fields:    
    3. The Liver-Immunity Nexus and Cancer Immunotherapy. Clin Cancer Res. 2022 01 01; 28(1):5-12. Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. PMID: 34285059; PMCID: PMC8897983.
      View in: PubMed   Mentions:    Fields:    
    4. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020 10 02; 5(52). Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA. PMID: 33008914; PMCID: PMC7755924.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    5. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Ann Surg Oncol. 2020 Oct; 27(11):4122-4130. Levine LS, Mahuron KM, Tsai KK, Wu C, Mattis DM, Pauli ML, Oglesby A, Lee JC, Spitzer MH, Krummel MF, Algazi AP, Rosenblum MD, Alvarado M, Daud AI. PMID: 32488521; PMCID: PMC8317618.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer. Cancer Immunol Immunother. 2019 Jul; 68(7):1087-1094. Chen YL, Huang WC, Lin FM, Hsieh HB, Hsieh CH, Hsieh RK, Chen KW, Yen MH, Lee J, Su S, Marfatia T, Chang SE, Sundar P, Patterson B, Watson D, Mei R, Javey M. PMID: 31089757; PMCID: PMC6584214.
      View in: PubMed   Mentions:
    7. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018 08; 67(8):1471-1480. Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. PMID: 29937434; PMCID: PMC6054443.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansAnimals
    8. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14). Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI. PMID: 28724802; PMCID: PMC5518562.
      View in: PubMed   Mentions: 19     Fields:    
    9. Shifting the Evolving CAR T Cell Platform into Higher Gear. Cancer Cell. 2015 Oct 12; 28(4):401-402. Holohan DR, Lee JC, Bluestone JA. PMID: 26461084.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    10. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 18(119):4133-41. Lee JC*, Pegram HJ*, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ . View Publication.
    11. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011 Apr 15; 71(8):2871-81. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. PMID: 21487038; PMCID: PMC3094720.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    12. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med. 2009 Mar; 15(3):338-44. Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, La Perle K, Larson SM, Sadelain M, Brentjens RJ. PMID: 19219023; PMCID: PMC2837150.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    13. Inventing New CARs: Analysis of Chimeric Antigen Receptor Gene-Targeted T cells Modified to Overcome Regulatory T cell Suppression in the Tumor Microenvironment. Yale University MD Thesis. 2009. Lee, James.
    14. Retroviral transduction of murine primary T lymphocytes. Methods Mol Biol. 2009; 506:83-96. Lee J, Sadelain M, Brentjens R. PMID: 19110621; PMCID: PMC5003426.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    James's Networks
    Concepts (95)
    Derived automatically from this person's publications.
    _
    Co-Authors (18)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _